We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BASF's Tinosorb S Gets FDA Nod as First New UV Filter in 27 Years
Read MoreHide Full Article
Key Takeaways
BASFY's Tinosorb S won FDA approval as the first new UV filter for U.S. consumers in 27 years.
Tinosorb S offers broad UVA and UVB protection with photostability during prolonged sun exposure.
BASFY gains new formulation opportunities for broad-spectrum sunscreens, including sensitive-skin products.
BASF SE’s (BASFY - Free Report) Bemotrizinol, marketed as Tinosorb S, has been approved by the U.S. Food and Drug Administration (FDA) as a sunscreen active ingredient. This approval serves as a landmark, paving the way for the introduction of the first new UV filter to American consumers in 27 years, a major advancement in sun protection technology.
Originally developed by Ciba Specialty Chemicals and later acquired by BASFY, Bemotrizinol, known chemically as Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, has been widely used around the world for years as it provides highly effective broad-range protection against both UVA and UVB radiation.
Tinosorb S is recognized for its exceptional efficacy and photostability, maintaining its effectiveness even during prolonged sun exposure. With absorption peaks at approximately 310 nm and 340 nm, it offers comprehensive protection against wavelengths responsible for skin damage and premature aging.
Tinosorb S also comes added with formulations for more photo-unstable UV filters, helping improve the performance of less stable sunscreen ingredients such as avobenzone. This capability is especially valuable in the U.S. market, where options for strong UVA protection have been limited. Together with avobenzone or Z-COTE zinc oxides, Tinosorb S is able to achieve a wavelength above 370 nm, providing broad-spectrum protection.
Its large molecular structure is another key advantage, which results in low percutaneous absorptionand a reduced risk of irritation. These characteristics make it an excellent choice for advanced sunscreen formulations designed for sensitive skin.
The FDA approval of Tinosorb S expands BASF’s sun care portfolio and provides formulators with new opportunities to create more effective, broad-spectrum sunscreen products for American consumers, incorporating years of photoprotection.
BASFY has gained 18.5% over the past year compared with the industry’s 7.4% growth.
Image Source: Zacks Investment Research
BASFY’s Zacks Rank & Key Picks
BASFY currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Albemarle Corporation (ALB - Free Report) , CF Industries Holdings, Inc. (CF - Free Report) andAvino Silver & Gold Mines Ltd. (ASM - Free Report) .
The Zacks Consensus Estimate for ALB’s 2026 earnings is pinned at $12.39 per share, indicating a 1,668.35% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 74.5%. ALB’s shares have jumped 179.5% over the past year.
The Zacks Consensus Estimate for CF’s 2026 earnings is pegged at $17.16 per share, indicating a rise of 83.14% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 11.42%. CF shares have gained 8.6% over the past year.
The Zacks Consensus Estimate for ASM’s current fiscal-year earnings is pinned at 39 cents per share, indicating a 34.48% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 125%.
View the Zacks #1 Rank List
Image: Bigstock
BASF's Tinosorb S Gets FDA Nod as First New UV Filter in 27 Years
Key Takeaways
BASF SE’s (BASFY - Free Report) Bemotrizinol, marketed as Tinosorb S, has been approved by the U.S. Food and Drug Administration (FDA) as a sunscreen active ingredient. This approval serves as a landmark, paving the way for the introduction of the first new UV filter to American consumers in 27 years, a major advancement in sun protection technology.
Originally developed by Ciba Specialty Chemicals and later acquired by BASFY, Bemotrizinol, known chemically as Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, has been widely used around the world for years as it provides highly effective broad-range protection against both UVA and UVB radiation.
Tinosorb S is recognized for its exceptional efficacy and photostability, maintaining its effectiveness even during prolonged sun exposure. With absorption peaks at approximately 310 nm and 340 nm, it offers comprehensive protection against wavelengths responsible for skin damage and premature aging.
Tinosorb S also comes added with formulations for more photo-unstable UV filters, helping improve the performance of less stable sunscreen ingredients such as avobenzone. This capability is especially valuable in the U.S. market, where options for strong UVA protection have been limited. Together with avobenzone or Z-COTE zinc oxides, Tinosorb S is able to achieve a wavelength above 370 nm, providing broad-spectrum protection.
Its large molecular structure is another key advantage, which results in low percutaneous absorptionand a reduced risk of irritation. These characteristics make it an excellent choice for advanced sunscreen formulations designed for sensitive skin.
The FDA approval of Tinosorb S expands BASF’s sun care portfolio and provides formulators with new opportunities to create more effective, broad-spectrum sunscreen products for American consumers, incorporating years of photoprotection.
BASFY has gained 18.5% over the past year compared with the industry’s 7.4% growth.
Image Source: Zacks Investment Research
BASFY’s Zacks Rank & Key Picks
BASFY currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the Basic Materials space are Albemarle Corporation (ALB - Free Report) , CF Industries Holdings, Inc. (CF - Free Report) andAvino Silver & Gold Mines Ltd. (ASM - Free Report) .
While ALB sports a Zacks Rank #1 (Strong Buy) at present, CF and ASM carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for ALB’s 2026 earnings is pinned at $12.39 per share, indicating a 1,668.35% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 74.5%. ALB’s shares have jumped 179.5% over the past year.
The Zacks Consensus Estimate for CF’s 2026 earnings is pegged at $17.16 per share, indicating a rise of 83.14% year over year. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 11.42%. CF shares have gained 8.6% over the past year.
The Zacks Consensus Estimate for ASM’s current fiscal-year earnings is pinned at 39 cents per share, indicating a 34.48% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 125%.